| Literature DB >> 24194749 |
Yun Liu1, Ji-Yao Wang, Wei Jiang.
Abstract
Background. During the past two decades, Klebsiella pneumoniae (K. pneumoniae) had surpassed Escherichia coli (E. coli) as the predominant isolate from patients with pyogenic liver abscess (PLA) in Asian countries, the United States, and Europe, and it tended to spread globally. Since the clinical symptom is atypical, the accurate and effective diagnosis and treatment of K. pneumoniae liver abscesses (KLAs) are very necessary. Methods. Here, we have comprehensively clarified the epidemiology and pathogenesis of KLA, put emphases on the clinical presentations especially the characteristic radiographic findings of KLA, and thoroughly elucidated the most effective antibiotic strategy of KLA. Results. K1 serotype is strongly associated with KLA especially in diabetic patients. Computed tomography (CT) and ultrasound (US) were two main diagnostic methods of KLA in the past. Most of KLAs have solitary, septal lobular abscesses in the right lobe of liver, and they are mainly monomicrobial. Broad-spectrum antibiotics combined with the US-guided percutaneous drainage of liver abscesses can increase their survival rates, but surgical intervention still has its irreplaceable position. Conclusion. The imaging features contribute to the early diagnosis, and the percutaneous intervention combined with an aminoglycoside plus either an extended-spectrum betalactam or a second- or third-generation cephalosporin is a timely and effective treatment of KLA.Entities:
Year: 2013 PMID: 24194749 PMCID: PMC3806164 DOI: 10.1155/2013/258514
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Demographic, clinical characteristics and treatment of patients with Klebsiella pneumoniae liver abscesses from case reports.
| Case | Age | Sex | Race | Underlying diseases | Symptom | Location of medical therapy | Outcome | Reference | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 64 | F | Filipino | Diabetes mellitus thrombocytosis | Fever, rigors, nausea, and myalgias | Right lobe | Piperacilin-tazobactam (3.37 g Q6h) + gentamicin (400 mg qd), ceftriaxone (2 g iv qd) + oralmetronidazole (500 mg iv four times daily) followed by levofloxacin and metronidazole for 4 wks | Survived | [ |
| 2 | 71 | M | Caucasian | Coronary artery disease | Fever, abdominal pain, and hypotension | Left lobe | Cefotetan (2 g BID) + oral levofloxacin (500 mg qd) for 8 wks | Survived | [ |
| 3 | 53 | M | Caucasian | Mitral valve prolapse and hypercholesterolemia | Fever, rigors, fatigue, malaise, night sweats, and tooth pain | Left lobe | Ceftriaxone + metronidazole for 4 wks, gentamicin for 2 wks, followed by oral ciprofloxacin for 1 month | Survived | [ |
| 4 | 64 | F | Filipino | Peptic ulcer disease, coronary artery disease, and hypertension | Fever, right abdominal pain, and anorexia | Left lobe | Ciprofloxacin (400 mg, iv, bid) + metronidazole (500 mg iv, tid), followed by oral ciprofloxacin + metronidazole for 6 wks | Survived | [ |
| 5 | 56 | M | Filipino | None | Fever, chills, night sweats, epigastric pain, and nausea | Right lobe | Piperacillin/tazobactam (q6h) + metronidazole (500 mg, q8h), gentamicin (180 mg, q18h), followed by oral levofloxacin (500 mg, qd) + metronidazole (500 mg, tid) for 6 wks | Survived | [ |
| 6 | 59 | F | Filipino | Diabetes mellitus | Fever, chills, anorexia, and fatigue | Left lobe | Piperacillin/tazobactam (3.375 g, q6h) + metronidazole (500 mg, q8h), ceftriaxone (2 g/day) + metronidazole (500 mg, q8h) for 4 wks, followed by oral levofloxacin (500 mg/day) for 3 months | Survived | [ |
| 7 | 55 | M | Argentinian | None | Fever and fatigue | NR | Ceftriaxone + metronidazole, followed by oral ciprofloxacin for 6 wks, percutaneous drainage | Survived | [ |
| 8 | 47 | F | Omani | None | Fever, chills, rigors, mild cough, poor oral intake, and inability to walk | Right lobe | Augmentin (2 g iv q6h)+ gentamicin (1.7 g IV q8h) for 3 wks, catheter drainage | Survived | [ |
| 9 | 58 | F | Omani | Diabetes millitus | Fever, malaise, and nausea | Right lobe | Amikacin (1 g IV q12h) + ceftazidime (1.5 g IV q8h for 5 days), followed by ciprofloxacin (0.5 g IV q12h for 12 days) and piperacillin/tazobactam (4.5 g iv q8h) for 15 days | Survived | [ |
| 10 | 62 | M | Irish | Peripheral vascular disease and excess alcohol intake | Abdominal pain, anorexia and nausea | NR | Piperacillin/tazobactam (4.5 g iv q8h) for 15 days | Survived | [ |
| 11 | 40 | M | Filipino | Diabetes mellitus | Fever, polydipsia, and polyuria | Right lobe | Ceftriaxone (2 g iv qd), oralciprofloxacin for 69 days; percutaneous drainage, intravenous gentamicin, and ciprofloxacin (400 mg, iv bid) for 5 days | Survived | [ |
| 12 | 55 | M | Chinese | Diabetes mellitus | Vomiting, abdominal pain, fever, and rigors | Right lobe | Oral ciprofloxacin for 36 days, oral cephalexin for 97 days, amoxicillin-clavulanic acid (1.2 g, iv, tid) + gentamicin (320 mg/day) + metronidazole (500 mg, iv, tid), followed by ceftriaxone (2 g/day·iv) + oral metronidazole (400 mg, bid), percutaneous drainage | Survived | [ |
| 13 | 58 | M | Japanese | Diabetes mellitus | Malaise | Right lobe | Meropenem (1 g iv q12h) for 6 days, cefmetazole (2 g iv Q8h), oral cefcapene pivoxil (100 mg, tid), and antibiotic treatment for 30 days | Survived | [ |
| 14 | 61 | F | Japanese | Diabetes mellitus | Fever, chills, and a slight headache | NR | Meropenem (1 g, iv, q8h) + linezolid (600 mg, iv, q12h), changed to ceftriaxone (2 g q12h) for 20 days, followed by oral cephalexin (250 mg q6h) for 31 days | Survived | [ |
| 15 | 43 | M | Japanese | None | Right hypochondriac and epigastric pain | Right lobe | Meropenem (1 g day iv) for 15 days + IV insulin, mg/day, and oral ciprofloxacin (400 mg/day) for 50 days | Survived | [ |
NR: not reported.
Genes associated with the serotypes of K. pneumonia.
| Gene | Comment | K1 | K2 | Non-K1/K2 | Reference |
|---|---|---|---|---|---|
| MagA | Capsular polysaccharide synthesis | + | § | § | [ |
| RmpA | Regulator of the mucoid phenotype | + | + | + | [ |
| kfu/PTS | Iron uptake system (kfu) and a phosphoenolpyruvate | + | − | + | [ |
| Aerobactin | An iron chelator | + | + | + | [ |
| AllS | Anaerobic metabolism of allantoin | + | − | − | [ |
| No. of isolates (%) ( | — | 63.40% | 14.20% | 22.40% | [ |
§: No data; −: lack of this gene.
Comparison of CT imaging characteristics between KLA and non-KLA reported from Hong Kong (38), Korea (30), Singapore (41), Taiwan (35), and China (1).
| Parameters | Hong Kong (38) ( | Korea (30) ( | Singapore (41) ( | China (1) ( | Taiwan (35) ( | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KLA (140) | Non-KLA (21) |
| KLA (59) | Non-KLA (70) |
| KLA (92) | Non-KLA (39) |
| KLA (73) | Non-KLA (37) |
| KLA (171) | Non-KLA (77) |
| |
| No. of abscess | 0.01 | <0.05 | |||||||||||||
| Solitary ( | — | — | — | — | — | — | 73 (79.3%) | 22 (56.4%) | 60 (82.2%) | 30 (81.1%) | NS | 125 (73.1%) | 45 (58.4%) | ||
| Multiple ( | — | — | — | — | — | — | 19 (20.7%) | 17 (43.6%) | 13 (17.8%) | 7 (18.9%) | NS | 46 (26.9%) | 32 (41.6%) | ||
| Location | 0.312 | 0.01 | NS | ||||||||||||
| Right | 97 (69.3%) | 15 (71.4%) | 0.42 | 41 (69.5%) | 49 (70.0%) | 76 (82.6%)§ | (61.5%)§ | 47 (64.4%) | 24 (64.9%)* | NS | 128 (74.9%) | 52 (67.5%) | |||
| Left | 31 (22.1%) | 4 (19.1%) | 0.38 | 14 (23.7%) | 16 (22.9%) | § | § | 11 (15.1%) | 5 (16.7%)* | NS | 34 (19.9%) | 19 (24.7%) | |||
| Both | 12 (8.6%) | 2 (9.5%) | 0.44 | 4 (6.8%) | 5 (7.1%) | 16 (17.4%) | 15 (38.5%) | 2 (2.7%)* | 1 (2.7%)* | NS | 9 (5.2%) | 6 (7.8%) | |||
| <5,72 (42.1%); | <5,36 (46.8%); | NS | |||||||||||||
| Size (cm) | 6.5 ± 2.8# | 7.4 ± 2.9# | 0.19 | — | — | — | 7.3 ± 2.8# | 7.8 ± 2.8# | 0.35 | 7.4 ± 2.4# | 7.4 ± 3.2# | NS | 5–10,87 (50.9%) | 5–10,37 (48.1%) | |
| Septations within abscess | 0.103 | 0.01 | — | ||||||||||||
| Unilocular | — | — | — | 9 (15.3%) | 19 (27.1%) | 5 (5.4%) | 11 (28.2%) | — | — | — | — | — | |||
| Multilocular | 84 (60%) | 13 (61.9%) | 0.43 | 50 (84.7%) | 51 (72.9%) | 87 (94.6%) | 28 (71.8%) | 41 (38.7%) | 20 (35.7%) | NS | — | — | |||
| Gas-formation in abscess | 13 (9.3%) | 2 (9.5%) | 0.49 | 52 (89.7%) | 64 (91.4%) | 0.536 | 11 (28.2%) | 6 (15.4%) | 0.58 | 24 (32.9%) | 5 (13.5%) | <0.05 | 7 (4.1%) | 4 (5.2%) | NS |
| Septal enhancement | — | — | — | 44 (74.6%) | 41 (58.6%) | 0.056 | — | — | — | 30 (41.1%) | 6 (16.2%) | <0.05 | — | — | — |
| Rim-enhancement | 68 (48.6%) | 12 (57.1%) | 0.23 | 20 (33.9%) | 43 (61.4%) | 0.004 | — | — | — | 28 (38.4%) | 12 (32.4%) | NS | — | — | — |
| Pneumobilia | 9 (6.4%) | 0 (0.0%) | 0.12 | — | — | — | 1 (1.1%) | 5 (12.8%) | 0.01 | 7 (9.6%) | 3 (8.1%) | NS | — | — | — |
| Thrombophlebitis | 2 (1.4%) | 1 (4.8%) | 0.13 | — | — | — | 28 (30.4%) | 2 (5.1%) | <0.01 | — | — | — | — | — | — |
—: There were no data in these references; §locations of right and left are not mentioned separately in reference [41]; #means ± standard; *there were other locations of abscess in addition to those mentioned in reference [1].
Figure 1Comparison of abdominal CT images between KLA and Non-KLA. (a) CT images of a 57-year-old male KLA patient with concomitant diabetes mellitus: circular shadow of low and uneven density can be seen in the caudate lobe near the second hepatic portal. With a diameter of 90 mm, a shadow of much lower density and gas cavities can be seen in the center of the abscess. During enhanced scanning, the margin and internal septations of abscess show a honeycomb-like structure. Intrahepatic bile ducts show slight dilation. (b) CT images of a 51-year-old female patient with E. coli liver abscess: irregular low-density lesion with a honeycomb-like structure can be seen in the right lobe of the liver. Obvious cystic wall enhancement can be seen during enhanced scanning. There is no stenosis or filling defect of hepatic vessels. (c) CT images of a 65-year-old female patient with Pseudomonas aeruginosa liver abscess: patchy shadow of low-and-even density and clear edge can be seen in the right lobe of the liver. By enhanced CT scan, the peripheral enhancement is more dramatic than the nonperipheral enhancement. Septation is visible inside the abscess, and hepatic blood vessels are evenly distributed. KLA: Klebsiella pneumoniae liver abscess; Non-KLA: non-Klebsiella pneumonia-induced pyogenic liver abscess.
Antibiotic treatment in patients with Klebsiella pneumoniae liver abscess and Streptococcus milleri liver abscess.
| KLA |
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hong Kong (38) ( | Singapore (4) ( | Taiwan (62) ( | Turkey (61) ( | Hong Kong (38) ( | ||||||
| Duration (days) | Efficiency | Duration (days) | Efficiency | Duration (days) | Efficiency | Duration (days) | Efficiency | Duration (days) | Efficiency | |
| Extended-spectrum penicillin* | 21.7 | 48 (34.3%) | — | — | — | — | — | 4 (4.7%) | 15.4 | 11 (52.4%) |
| First- and second-generation cephalosporins§ | 21.7 | 30 (21.4%) | 32 ± 13 | 24 (22.0%) | — | 104 (94.5%) | — | — | 15.4 | 4 (19%) |
| Third- and fourth-generation cephalosporins▲ | 21.7 | 50 (35.7%) | 32 ± 13 | 71 (65.1%) | — | 4 (3.6%) | — | 5 (5.9%) | 15.4 | 3 (14.3%) |
|
Carbapenems | — | — | 32 ± 13 | 13 (11.9%) | — | — | — | 42 (49.4%) | — | — |
| Aminoglycosides# | — | — | — | 1 (0.9%) | — | 104 (94.5%) | — | 2 (2.4%) | — | — |
| Quinolone** | — | — | — | — | — | — | — | 11 (12.9%) | — | — |
*Piperacillin-tazobactam, ticarcillin-clavulanate; §cefazolin; ▲ceftriaxone, cefepime; ∧ertapenem, meropenem; #amikacin; **ciprofloxacin.